Intellectual Property

Patent Portfolio

GlycoNex's glycan-directed oncology programs are protected by 36 granted patents across multiple jurisdictions, plus published and pending applications. Granted patent numbers are listed below for partner due diligence.

Antibody Family

GNX102 / GNX1021 Antibody Family

The anti-branched Lewis B/Y therapeutic antibody behind lead ADC GNX1021, together with its antibody-drug conjugate composition and method-of-use applications.

Granted patents (9)

Granted patents for the GNX102 / GNX1021 antibody family — jurisdiction and patent number
Jurisdiction Patent No.
USUS11440967B2
USUS11643471B2
CNCN112533948B
JPJP7696404B2
KR10-2480815
TWI842712
MX424537
RU2803097
IL279109

A further 10 applications are pending, including in Australia, Brazil, Canada, Europe (EPO), India, Singapore, and the United States.

Antibody Family

GNX8

An anti-extended type I glycosphingolipid antibody covered by 27 granted patents worldwide; patents held by GlycoNex and licensed to Otsuka Pharmaceutical since 2009.

Representative grants (6 of 27)

Representative granted patents for GNX8 — jurisdiction and patent number, six of twenty-seven
Jurisdiction Patent No.
USUS 8163497 B2
EPEP 2324060 B1
JPJP 5611210 B2
TWTW I433684 B
CNCN 102282172 B
KRKR 101442323 B1

Complete patent documentation under confidentiality

Complete patent documentation is available to qualified partners under confidentiality. Reach out to discuss due diligence access across GlycoNex's glycan-directed antibody and ADC programs.

Partnering & Licensing →